VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer

Vemurafenib, an inhibitor of mutant BRAF activity, is a promising anticancer agent for patients with BRAF-mutant metastatic melanoma. However, it is less effective in BRAF-mutant thyroid cancer, and the reason for this discrepancy is not yet fully elucidated. By RNA sequencing analysis, we identifie...

Full description

Bibliographic Details
Main Authors: Shitu Chen, Xingyun Su, Xiaoxia Jiang, Tuo Zhang, Irene Min, Yongfeng Ding, Xumeng Wang, Zhuochao Mao, Jiang Cao, Xiaodong Teng, Thomas J. Fahey, III, Weibin Wang, Lisong Teng
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319303110

Internet

http://www.sciencedirect.com/science/article/pii/S1936523319303110

Similar Items